Protocol Ledger

NCT07692867 · Phase III · COMPLETED

Efficacy and Safety Study of Tunodafil Hydrochloride Tablets in Erectile Dysfunction

Interventional Phase III clinical trial protocol NCT07692867 sponsored by Yangtze River Pharmaceutical Group Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-01 Enrollment: 780 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07692867
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)780 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07692867
Protocol FieldVerified Registry Value
NCT IdentifierNCT07692867
Consolidated Lead SponsorYangtze River Pharmaceutical Group Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment780 participants (ACTUAL)
Registered Start Date2021-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI